壹生大学
手机号已经完成验证,请完善个人资料!
壹生大学肿瘤学院妇科恶性肿瘤引起的腹水处理(下)
妇科恶性肿瘤引起的腹水处理(下)
2757 观看 发布时间 2019-06-13

  • 课程介绍
  • 讲者介绍
  • 评价

内容提要:

1. 卵巢癌的手术治疗

2. 卵巢癌的辅助化疗

3. 卵巢癌的维持治疗

(最下方有课程中涉及的文献信息)


请添加课程助手(微信号:Rachelsunyue)为好友,邀您加入“恶性胸腹水处理微信交流群”。

ea5b8e40-fe43-4ec3-baf3-102f00971b23.jpeg

1-2 袁光文.png

文献资料:

1. Bristow, R.E., et al., Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 2002. 20(5): p. 1248-59.

2. Burger, R.A., et al., Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med, 2011. 365(26): p. 2473-83.

3. du Bois, A., et al., Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol, 2014. 32(30): p. 3374-82.

4. Harter, P., et al., A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. N Engl J Med, 2019. 380(9): p. 822-832.

5. Kim, M.K., et al., Management of Endometrial Hyperplasia: A Survey of Members of the Korean Gynecologic Oncology Group. Int J Gynecol Cancer, 2015. 25(7): p. 1277-84.

6. Konstantinopoulos, P.A., et al., Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov, 2015. 5(11): p. 1137-54.

7. Moore, K., et al., Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med, 2018. 379(26): p. 2495-2505.

8. Perren, T.J., et al., A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med, 2011. 365(26): p. 2484-96.

9. van Driel, W.J., et al., Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med, 2018. 378(3): p. 230-240.


购买课程
价格:¥0元